nach oben

Hepatology International

Erschienen in:

01.07.2014 | Review Article

Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma

verfasst von: Ivonne Nel, Paul David, Guido G. H. Gerken, Joerg F. Schlaak, Andreas-Claudius Hoffmann

Erschienen in: Hepatology International | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Circulating tumor cells (CTC) and cancer stem cells (CSC) have been proposed as tools for detection and characterization of disease and individualization of therapy in patients with many solid tumors. Several automated and semi-automated techniques for identification and isolation of these cells from blood have been proposed and reviewed mostly focusing on their feasibility. In this mini review we summarize the recent relevant literature on this topic and discuss the clinical usability of measuring CTC and CSC in peripheral blood in patients with hepatocellular carcinoma (HCC). Besides literature, the basis for this evaluation was the authors’ experience with treating HCC and research experience on CSC and CTC. Few original reports and reviews have been published focusing on CTC and CSC in HCC. Though HCC is one of the five most common malignancies worldwide only recently these cells have come into focus for detection and characterization of this disease that is characterized by high plasticity and malignancy. A focused and prospective validation of the clinical usability of detecting these cells in HCC is still needed, but results seem promising that they may add great benefit for early detection and individualization of therapy.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90PubMedCrossRef

Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436–2443PubMedCrossRef

Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022PubMedCentralPubMedCrossRef

Hoffmann AC, Vallbohmer D, Grimminger P, Metzger R, Prenzel KL, Hoelscher AH, et al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 2010;11:341–347PubMedCrossRef

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580–584PubMedCentralPubMedCrossRef

Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651–2660PubMed

Christofori G. New signals from the invasive front. Nature 2006;441:444–450PubMedCrossRef

Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 2011;15:1066–1070PubMedCrossRef

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–715PubMedCentralPubMedCrossRef

10.

Nel I, Gauler T, Hoffmann AC. Circulating tumor cell composition and outcome in patients with solid tumors. Int J Clin Pharmacol Ther. 2014;52:74–75PubMedCrossRef

11.

Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci 2010;1210:66–77PubMedCrossRef

12.

Bitting RL, Boominathan R, Rao C, Kemeny G, Foulk B, Garcia-Blanco MA, et al. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 2013;64:129–136PubMedCrossRef

13.

Wu LJ, Pan YD, Pei XY, Chen H, Nguyen S, Kashyap A, et al. Capturing circulating tumor cells of hepatocellular carcinoma. Cancer Lett 2012;326:17–22PubMedCrossRef

14.

Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol 2012;2012:684802PubMedCentralPubMedCrossRef

15.

Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 2012;39:449–460PubMedCrossRef

16.

Alix-Panabieres C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 2014;14:57–62PubMedCrossRef

17.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. Journal of Thoracic Oncology 2012;7:306–315PubMedCrossRef

18.

Nel I, Ertlel JM, Baba HA, Weber F, Sitek B, Stephan C, et al. A novel method for the detection of different subgroups of circulating tumor cells in patients with hepatocellular carcinoma. Hepatology 2012;56:457A

19.

Nel I, Baba HA, Ertle J, Weber F, Sitek B, Eisenacher M, et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013;6:420–428PubMedCentralPubMedCrossRef

20.

Campos M, Luque R, Jimenez J, Martinez R, Warleta F, Sanchez-Quesada C, et al. Simultaneous phenotypic and genetic characterization of single circulating tumor cells from colon cancer patients. Histol Histopathol 2013;6(5):872–879

21.

Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012;9:016003PubMedCentralPubMedCrossRef

22.

Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, et al. Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin Cancer Res 2003;9:3004–3011PubMed

23.

Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004;39:792–797PubMedCrossRef

24.

Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W, et al. Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR. J Clin Gastroenterol 2007;41:783–788PubMedCrossRef

25.

Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47:919–928PubMedCrossRef

26.

Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011;17:3783–3793PubMedCrossRef

27.

Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, Wu WZ, et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683–2691PubMedCrossRef

28.

Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013;57:1458–1468PubMedCrossRef

29.

Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 2013;144(1031–1041):e1010

30.

Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013;133:2165–2171PubMedCrossRef

31.

Schulze K, Beneken C, Staufer K, Nashan B, Lohse AW, Pantel K, et al. Detection of Epcam-Positive Circulating Tumor Cells in Patients with Hepatocellular Carcinoma—a Pilot Study. Hepatology 2011;54:1357a

32.

Gao P, Jiao SC, Bai L, Wang H, Jing FF, Yang JL. Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J Int Med Res 2013;41:923–933PubMedCrossRef

33.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559–1564PubMedCrossRef

34.

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90 + cancer stem cells in human liver cancer. Cancer Cell 2008;13:153–166PubMedCrossRef

35.

Yoon SK. The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma. Gut Liver 2012;6:29–40PubMedCentralPubMedCrossRef

36.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012–1024PubMedCentralPubMedCrossRef

37.

Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/progenitor cells are highly enriched in CD133 + CD44 + population in hepatocellular carcinoma. Int J Cancer 2010;126:2067–2078PubMedCrossRef

38.

Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Organizing Committee of Japan-Korea Liver S. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008;75(Suppl 1):13–16PubMedCrossRef

39.

Libbrecht L, Roskams T. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 2002;13:389–396PubMedCrossRef

40.

Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 2011;208:1963–1976PubMedCentralPubMedCrossRef

41.

Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells–perspectives on current status and future directions: aACR Workshop on cancer stem cells. Cancer Res 2006;66:9339–9344PubMedCrossRef

42.

Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831–10839PubMedCrossRef

43.

Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013;34:732–740PubMedCentralPubMedCrossRef

44.

Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100–109PubMedCentralPubMedCrossRef

45.

Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int 2009;29:955–965PubMedCrossRef

46.

Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007;67:11687–11695PubMedCrossRef

47.

Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009;11:373–81PubMedCrossRef

Titel: Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma
verfasst von: Ivonne Nel
Paul David
Guido G. H. Gerken
Joerg F. Schlaak
Andreas-Claudius Hoffmann
Publikationsdatum: 01.07.2014
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 3/2014
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-014-9539-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion

Yttrium-90 radioembolization for hepatocellular carcinoma in hepatitis B: commentary on a 103-patient Asian cohort

Interferon for Chinese patients with chronic hepatitis B e antigen-positive diseases—the controversy arises again?

Neonatal streptozotocin treatment causes type 1 diabetes and subsequent hepatocellular carcinoma in DIAR mice fed a normal diet

Procalcitonin as a marker of sepsis in alcoholic hepatitis